iSpecimen, TriMetis Life announces strategic partnership

iSpecimen announced that it entered into a pilot program agreement with TriMetis Life Sciences. This agreement aims to establish a strategic partnership between iSpecimen and TriMetis, providing opportunities for iSpecimen, its suppliers and customers to utilize technology solutions from TriMetis. By combining iSpecimen’s global network of suppliers and researchers with TriMetis’ AI-powered, automated digital pathology solutions, this partnership is working to address industry challenges, reduce the risk of errors associated with manual processes and revolutionize tissue assessment for preclinical research. “This pilot program exemplifies the fusion of two online portals, leveraging cutting-edge technological tools to both enhance customer service and elevate industry standards,” said Tracy Curley, Chief Executive Officer of iSpecimen. Ms. Curley continued, “For both iSpecimen and TriMetis, the focus is first and foremost on establishing best practices for quality control and assurance. By incorporating AI readings and images, our goal is to enhance the standardization of tissue-based oncology samples on the iSpecimen Marketplace(R), contributing to a transformative shift in the quality assessments of tissue samples. Our collaboration with TriMetis represents a milestone in advancing tissue research quality, streamlining procurement processes and setting new industry-wide benchmarks through this innovative process that will further increase accuracy.”